Status unknownNCT04624971Updated Nov 12, 2020

A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era

An observational study in Diffuse Large B Cell Lymphoma, sponsored by Sun Yat-sen University. Status unknown at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-12.

Sponsored by Sun Yat-sen University · Observational

The sponsor has not verified this record recently (last verified Nov 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Study type: Observational
Model: Cohort
Time perspective: Retrospective
Enrollment: 2,000
Ages: 18 Years and older
Sex: All

Study summary

The purpose of this study is to determine the predictive value of a model of Nomogram Prognostic Index (NPI) in patients with Diffuse Large B cell lymphoma.

Conditions studied

Diffuse Large B Cell Lymphoma

Browse trials for

In context

Lymphoma

5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 136 across 625 observational studies indexed under Lymphoma.

Browse Lymphoma studies →

Lead sponsor

Sun Yat-sen University is the lead sponsor of 1,644 studies on the registry; 602 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Probability sample

Study population

patients with clinical information available

Inclusion criteria

histologically confirmed diagnosis of CD20+ DLBCL

Exclusion criteria

Exclusion Criteria:

primary central nervous system lymphoma
"double-hit" lymphoma

Study design

Observational model: Cohort
Time perspective: Retrospective
Enrollment: 2,000 participants (estimated)
Patient registry: No

What researchers measure

Primary outcomes

Overall survival
Time frame: 5-year

Study locations

3 sites

Guangdong General Hospital
Guangzhou, Guangdong 510000, China
- Wenyu Li, MD · Contact
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,
Guangzhou, 51000, China
- Zhihua Li, PhD · Contact
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,
Guangzhou, 51000, China
- Qing qing Cai, MD · Contact

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Nov 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT04624971
Lead sponsor: Sun Yat-sen University
Responsible party: Qingqing Cai (Chief physician, Sun Yat-sen University) — Principal investigator
First posted: Nov 12, 2020
Start date: Nov 2020 (estimated)
Primary completion: Nov 2020 (estimated)
Completion: Nov 2020 (estimated)
Last update: Nov 12, 2020

Study contacts

Qingqing Cai, MD

Contact

caiqq@sysucc.org.cn

0086-20-87342823

Oversight

FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lymphoma→

Other studies from this sponsor

Sun Yat-sen University

Start the discussion